Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593 · PHOENIX Phase 3Active, not recruiting
- Lead sponsor
- Belite Bio, Inc (Industry)
- Enrollment
- 429 (estimated)
- Start date
- 27 Jul 2023
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 31 Aug 2027
- Last update posted
- 7 Jan 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- Tinlarebant Drug
- Placebo Drug
Conditions and primary outcome
- Geographic Atrophy
Primary outcome
To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size (From baseline to Month 24])
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05949593.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05949593 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.